Skip to main content
. 2015 Nov 23;14:77–87. doi: 10.1007/s40258-015-0204-3

Fig. 2.

Fig. 2

Cost-effectiveness plane for varenicline (multiple quit attempts) versus market mix. QALYs quality-adjusted life-years